Literature DB >> 12434407

Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells.

Wendy S Putnam1, Srinivasan Ramanathan, Lin Pan, Lori H Takahashi, Leslie Z Benet.   

Abstract

Bidirectional transport studies were conducted to determine whether substrates of five intestinal transporters showed carrier-mediated asymmetric transport across MDCK (Madin-Darby canine kidney) cell monolayers grown under standard conditions. Drug concentrations were quantitated using liquid scintillation counting, liquid chromatography/mass spectrometry/mass spectrometry, or liquid chromatography/mass spectrometry. In the presence of a pH gradient, benzoic acid exhibited net apical-to-basolateral transport, with apparent permeability ratios (apical-to-basolateral permeability/basolateral-to-apical permeability) ranging from 14 to 25. The addition of valproic acid reduced the permeability ratio by 70-90%. Cephalexin transport also exhibited net absorption in the presence of a pH gradient, with apparent permeability ratios ranging from 14 to 71, depending on growth conditions. Radiolabeled phenylalanine exhibited a low level of carrier-mediated absorption with an apparent permeability ratio of 1.8 that was reduced to 1.0 in the presence of unlabeled L-phenylalanine. Taurocholic acid did not exhibit carrier-mediated absorption. Cyclosporine and fexofenadine exhibited P-glycoprotein-mediated efflux from both MDCK and Caco-2 cells, which was more sensitive to inhibition in MDCK cells. These results suggest that although MDCK cell monolayers may be a useful model for evaluating transport by the absorptive monocarboxylic acid and peptide transporters and the efflux transporter, P-glycoprotein, they are not useful for predicting large neutral amino acid or bile acid transport in the intestine. Copyright 2002 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 91:2622-2635, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12434407     DOI: 10.1002/jps.10264

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Authors:  Mikiko Shimizu; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2006-06-23       Impact factor: 4.335

2.  Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.

Authors:  Christine Y Malati; Sarah M Robertson; Jennifer D Hunt; Cheryl Chairez; Raul M Alfaro; Joseph A Kovacs; Scott R Penzak
Journal:  J Clin Pharmacol       Date:  2011-06-06       Impact factor: 3.126

Review 3.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

Authors:  Mikiko Shimizu; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

5.  Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein.

Authors:  David L Bourdet; Dhiren R Thakker
Journal:  Pharm Res       Date:  2006-06-08       Impact factor: 4.200

6.  Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery.

Authors:  Shuanghui Luo; Viral S Kansara; Xiaodong Zhu; Nanda K Mandava; Dhananjay Pal; Ashim K Mitra
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

7.  Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT).

Authors:  Anand Balakrishnan; Daniel J Sussman; James E Polli
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

8.  The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers.

Authors:  Tomonori Tateishi; Masatomo Miura; Toshio Suzuki; Tsukasa Uno
Journal:  Br J Clin Pharmacol       Date:  2008-02-20       Impact factor: 4.335

9.  Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier.

Authors:  Rajendra S Kadam; Robert I Scheinman; Uday B Kompella
Journal:  Mol Pharm       Date:  2012-10-15       Impact factor: 4.939

10.  Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.

Authors:  Takashi Sakugawa; Masatomo Miura; Nobuo Hokama; Toshio Suzuki; Tomonori Tateishi; Tsukasa Uno
Journal:  Br J Clin Pharmacol       Date:  2009-01-23       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.